This Dividend King Just Announced Great News for Investors
2026-10-26 17:58
•Prosper Junior Bakiny •The Motley Fool
••••• • Axe Cap view
Abbott’s Spin-Off Boosts Growth Story, What It Means for Rand Investors
Abbott Laboratories’ decision to separate its nutrition business sharpens its growth focus, a move worth noting from a rand investor’s perspective.
Abbott Laboratories’ recent announcement to spin off its nutrition segment is more than a tidy corporate reshuffle. The move should free up capital and management focus to double down on its lucrative medical device business, including its FreeStyle Libre diabetes monitors and cancer diagnostics via Exact Sciences. This sharper focus supports sustained earnings growth, underlined by 7% revenue and 9% EPS improvements in Q3. For investors tracking US-dollar exposure through USD/ZAR, this matters: a stronger Abbott earnings outlook could keep upward pressure on the rand, as South African fund managers adjust foreign holdings with more conviction. Rand investors should consider the USD/ZAR pair closely since higher US tech and healthcare earnings often correlate with moderate rand strength. Watch for any unexpected weakness in the rand, which could undermine returns. The main risk is a sharper-than-expected US dollar rally that would mute gains from Abbott’s positive news. this is just our opinion and not financial advice
Watch the USD/ZAR closely and consider adding US healthcare exposure selectively, as Abbott’s earnings growth supports dollar assets. Within South Africa, prefer banks like Standard Bank and FirstRand that benefit from rand strength and foreign inflows. Trim rand-hedged tech exposure if the dollar spikes.
- USD/ZAR
- Standard Bank
- Abbott Laboratories (ABT)
- Sudden USD appreciation against ZAR
- Global healthcare regulatory setbacks
6/10
Abbott Laboratories reported solid Q3 2026 results with 7% sales growth and 9% higher adjusted EPS. The company announced a significant decision to spin off its struggling nutrition business into a standalone company, which should improve growth prospects. Abbott's core medical device segment, particularly its FreeStyle Libre diabetes care products and recent Exact Sciences acquisition for cancer diagnostics, positions the company well for future growth. As a Dividend King with 50+ consecutive years of dividend increases, Abbott remains attractive for income investors.
Our take is based on reporting first published by The Motley Fool.